Overview

A Study of BGM0504 in Participants With Obesity

Status:
RECRUITING

Trial end date:
2026-01-11

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of BGM0504 compared with Tirzepatide in adult participants who have obesity without diabetes after 26 weeks of treatment.

Phase:

PHASE2

Details

Lead Sponsor:

BrightGene Bio-Medical Technology Co., Ltd.

Treatments:

Tirzepatide